StockNews.com assumed coverage on shares of Cutera (NASDAQ:CUTR – Free Report) in a research note issued to investors on Sunday morning. The firm issued a sell rating on the medical device company’s stock.
Cutera Stock Up 24.1 %
Shares of CUTR stock opened at $0.48 on Friday. Cutera has a fifty-two week low of $0.28 and a fifty-two week high of $4.97. The firm’s 50 day moving average price is $0.41 and its two-hundred day moving average price is $0.80. The stock has a market cap of $9.77 million, a price-to-earnings ratio of -0.07 and a beta of 1.31.
Institutional Trading of Cutera
Large investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can lifted its stake in shares of Cutera by 14.2% during the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock worth $455,000 after purchasing an additional 35,248 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of Cutera by 164.5% in the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after buying an additional 70,870 shares in the last quarter. Finally, Ground Swell Capital LLC purchased a new stake in shares of Cutera during the 2nd quarter valued at about $37,000. 90.70% of the stock is currently owned by institutional investors and hedge funds.
Cutera Company Profile
Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.
Read More
- Five stocks we like better than Cutera
- Consumer Discretionary Stocks Explained
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.
